SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376625" target="_blank" >RIV/00216208:11110/18:10376625 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00102807 RIV/00064165:_____/18:10376625

Výsledek na webu

<a href="https://doi.org/10.1016/j.ygyno.2018.01.001" target="_blank" >https://doi.org/10.1016/j.ygyno.2018.01.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ygyno.2018.01.001" target="_blank" >10.1016/j.ygyno.2018.01.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm

Popis výsledku v původním jazyce

Objectives. The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2 cm on a large cohort of patients. Methods. Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. Results. The study included 350 patients with stages pTla - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors &lt; 2 cm, 2-3.9 cm, and &gt;= 4 cm (79%, 83%, 76%) (P = 0.460). There were only two cases with false-negative SLN ultrastaging for pelvic IN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P = 0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P = 0.510). Conclusions. If the tracer application technique is adjusted in larger tumors, SIN biopsy can be equally reliable in pelvic IN staging in tumors smaller and larger than 2 cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors &lt; 2 cm, 2-3.9 cm, and cm.

Název v anglickém jazyce

SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm

Popis výsledku anglicky

Objectives. The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2 cm on a large cohort of patients. Methods. Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. Results. The study included 350 patients with stages pTla - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors &lt; 2 cm, 2-3.9 cm, and &gt;= 4 cm (79%, 83%, 76%) (P = 0.460). There were only two cases with false-negative SLN ultrastaging for pelvic IN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P = 0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P = 0.510). Conclusions. If the tracer application technique is adjusted in larger tumors, SIN biopsy can be equally reliable in pelvic IN staging in tumors smaller and larger than 2 cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors &lt; 2 cm, 2-3.9 cm, and cm.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

<a href="/cs/project/NV16-31643A" target="_blank" >NV16-31643A: Biopsie sentinelové uzliny versus systematická pánevní lymfadenektomie v léčbě časných stádií karcinomu děložního hrdla</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Gynecologic Oncology

ISSN

0090-8258

e-ISSN

—

Svazek periodika

148

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

456-460

Kód UT WoS článku

000428005300005

EID výsledku v databázi Scopus

2-s2.0-85040686409